US FDA grants Orphan Drug Designation for cannabidiol (Zygel) for the treatment of 22q11.2 deletion syndrome

22q11.2 deletion syndrome is a rare midline condition featuring physical abnormalities and debilitating neuropsychiatric and behavioural symptoms. Zygel is a transdermal cannabidiol preparation that is also in development for the treatment of Fragile X syndrome.


Biospace Inc.